Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 54


The Reply.

Kalra PR, Greenlaw N, Ford I, Steg PG, Fox KM.

Am J Med. 2018 Mar;131(3):e129. doi: 10.1016/j.amjmed.2017.09.019. No abstract available.


Clinical characteristics, treatment and 2-year outcomes in Malaysian and Bruneian patients with stable coronary artery within the worldwide CLARIFY registry.

Chee KH, Choo GH, Jamaluddin ANB, Mahendran K, Greenlaw N, Chandran A.

Med J Malaysia. 2017 Oct;72(5):282-285.


Relationships Between Components of Blood Pressure and Cardiovascular Events in Patients with Stable Coronary Artery Disease and Hypertension.

Vidal-Petiot E, Greenlaw N, Ford I, Ferrari R, Fox KM, Tardif JC, Tendera M, Parkhomenko A, Bhatt DL, Steg PG.

Hypertension. 2018 Jan;71(1):168-176. doi: 10.1161/HYPERTENSIONAHA.117.10204. Epub 2017 Oct 30.


Management and clinical outcome of stable coronary artery disease in Austria : Results from 5 years of the CLARIFY registry.

Lang IM, Badr-Eslam R, Greenlaw N, Young R, Steg PG.

Wien Klin Wochenschr. 2017 Dec;129(23-24):879-892. doi: 10.1007/s00508-017-1248-1. Epub 2017 Sep 14.


Management and prevalence of long-term conditions in primary health care for adults with intellectual disabilities compared with the general population: A population-based cohort study.

Cooper SA, Hughes-McCormack L, Greenlaw N, McConnachie A, Allan L, Baltzer M, McArthur L, Henderson A, Melville C, McSkimming P, Morrison J.

J Appl Res Intellect Disabil. 2018 Jan;31 Suppl 1:68-81. doi: 10.1111/jar.12386. Epub 2017 Jul 20.


Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.

Petrie JR, Chaturvedi N, Ford I, Brouwers MCGJ, Greenlaw N, Tillin T, Hramiak I, Hughes AD, Jenkins AJ, Klein BEK, Klein R, Ooi TC, Rossing P, Stehouwer CDA, Sattar N, Colhoun HM; REMOVAL Study Group.

Lancet Diabetes Endocrinol. 2017 Aug;5(8):597-609. doi: 10.1016/S2213-8587(17)30194-8. Epub 2017 Jun 11. Erratum in: Lancet Diabetes Endocrinol. 2017 Aug;5(8):e5. Lancet Diabetes Endocrinol. 2017 Nov;5(11):e7.


Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease.

Sorbets E, Greenlaw N, Ferrari R, Ford I, Fox KM, Tardif JC, Tendera M, Steg PG; CLARIFY Investigators.

Clin Cardiol. 2017 Oct;40(10):797-806. doi: 10.1002/clc.22730. Epub 2017 May 31.


Differences in outcomes in patients with stable coronary artery disease managed by cardiologists versus noncardiologists. Results from the international prospective CLARIFY registry.

Parma Z, Steg PG, Greenlaw N, Ferrari R, Ford I, Fox K, Tardif JC, Morais J, Gamba MA, Kääb S, Tendera For The Clarify Investigators M.

Pol Arch Intern Med. 2017 Jan 20;127(2):107-114. doi: 10.20452/pamw.3902. Epub 2017 Jan 20.


Hemoglobin and Change in Hemoglobin Status Predict Mortality, Cardiovascular Events, and Bleeding in Stable Coronary Artery Disease.

Kalra PR, Greenlaw N, Ferrari R, Ford I, Tardif JC, Tendera M, Reid CM, Danchin N, Stepinska J, Steg PG, Fox KM; ProspeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease (CLARIFY) Investigators.

Am J Med. 2017 Jun;130(6):720-730. doi: 10.1016/j.amjmed.2017.01.002. Epub 2017 Jan 19.


A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease.

Thomas KS, Batchelor JM, Bath-Hextall F, Chalmers JR, Clarke T, Crowe S, Delamere FM, Eleftheriadou V, Evans N, Firkins L, Greenlaw N, Lansbury L, Lawton S, Layfield C, Leonardi-Bee J, Mason J, Mitchell E, Nankervis H, Norrie J, Nunn A, Ormerod AD, Patel R, Perkins W, Ravenscroft JC, Schmitt J, Simpson E, Whitton ME, Williams HC.

Southampton (UK): NIHR Journals Library; 2016 Dec.


Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial.

Petrie JR, Chaturvedi N, Ford I, Hramiak I, Hughes AD, Jenkins AJ, E Klein B, Klein R, Ooi TC, Rossing P, Sattar N, Stehouwer CD, Colhoun HM; REMOVAL Trial Team.

Diabetes Obes Metab. 2017 Apr;19(4):509-516. doi: 10.1111/dom.12840. Epub 2017 Feb 17.


Is speed of healing a good predictor of eventual healing of pyoderma gangrenosum?

Wilkes SR, Williams HC, Ormerod AD, Craig FE, Greenlaw N, Norrie J, Mitchell EJ, Mason JM, Thomas KS; United Kingdom Dermatology Clinical Trials Network STOP GAP team.

J Am Acad Dermatol. 2016 Dec;75(6):1216-1220.e2. doi: 10.1016/j.jaad.2016.07.049. Epub 2016 Oct 11.


Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT).

MacDonald TM, Hawkey CJ, Ford I, McMurray JJV, Scheiman JM, Hallas J, Findlay E, Grobbee DE, Hobbs FDR, Ralston SH, Reid DM, Walters MR, Webster J, Ruschitzka F, Ritchie LD, Perez-Gutthann S, Connolly E, Greenlaw N, Wilson A, Wei L, Mackenzie IS.

Eur Heart J. 2017 Jun 14;38(23):1843-1850. doi: 10.1093/eurheartj/ehw387. Erratum in: Eur Heart J. 2016 Dec 24;:.


Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study.

Vidal-Petiot E, Ford I, Greenlaw N, Ferrari R, Fox KM, Tardif JC, Tendera M, Tavazzi L, Bhatt DL, Steg PG; CLARIFY Investigators.

Lancet. 2016 Oct 29;388(10056):2142-2152. doi: 10.1016/S0140-6736(16)31326-5. Epub 2016 Aug 30.


Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study.

Thomas KS, Ormerod AD, Craig FE, Greenlaw N, Norrie J, Mitchell E, Mason JM, Johnston GA, Wahie S, Williams HC; UK Dermatology Clinical Trials Network's STOP GAP Team.

J Am Acad Dermatol. 2016 Nov;75(5):940-949. doi: 10.1016/j.jaad.2016.06.016. Epub 2016 Aug 5.


Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-COG study): A pilot randomised controlled trial.

Cooper SA, Ademola T, Caslake M, Douglas E, Evans J, Greenlaw N, Haig C, Hassiotis A, Jahoda A, McConnachie A, Morrison J, Ring H, Starr J, Stiles C, Sirisena C, Sullivan F.

Trials. 2016 Jul 29;17:370. doi: 10.1186/s13063-016-1370-9.


Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.

McMurray JJ, Krum H, Abraham WT, Dickstein K, Køber LV, Desai AS, Solomon SD, Greenlaw N, Ali MA, Chiang Y, Shao Q, Tarnesby G, Massie BM; ATMOSPHERE Committees Investigators.

N Engl J Med. 2016 Apr 21;374(16):1521-32. doi: 10.1056/NEJMoa1514859. Epub 2016 Apr 4.


Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial.

Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, Martinez F, Starling RC, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M; PARADIGM-HF Investigators and Committees.

Circ Heart Fail. 2016 Jan;9(1). pii: e002560. doi: 10.1161/CIRCHEARTFAILURE.115.002560.


Management of coronary artery disease patients in Latvia compared with practice in Central-Eastern Europe and globally: analysis of the CLARIFY registry.

Erglis A, Mintale I, Latkovskis G, Balode I, Jegere S, Bajare I, Rozenbergs A, Greenlaw N, Ferrari R, Steg PG; CLARIFY registry investigators.

Medicina (Kaunas). 2015;51(4):240-6. doi: 10.1016/j.medici.2015.05.004. Epub 2015 Aug 4.


Practice nurse health checks for adults with intellectual disabilities: a cluster-design, randomised controlled trial.

Cooper SA, Morrison J, Allan LM, McConnachie A, Greenlaw N, Melville CA, Baltzer MC, McArthur LA, Lammie C, Martin G, Grieve EA, Fenwick E.

Lancet Psychiatry. 2014 Dec;1(7):511-21. doi: 10.1016/S2215-0366(14)00078-9. Epub 2014 Dec 3.


Supplemental Content

Loading ...
Support Center